Friday, July 31, 2026

Korean Firms Accelerate U.S. Rare Earth Push to Cut Reliance on China

South Korean firms are establishing rare earth production hubs in the U.S. to reduce reliance on China, supported by government funding.

Digital Deception: AI-Powered Propaganda Targets Fukushima Waters

A Chinese organization used AI technology to spread posts criticizing the release of contaminated water from the Fukushima.

Kim Jong Un Reaffirms Strengthened North Korea-China Ties with Wang Yi: What This Means for Regional Stability

Kim Jong Un met with Chinese Foreign Minister Wang Yi, reinforcing North Korea-China ties and emphasizing bilateral cooperation.

Tag: Celltrion

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

A 90-Minute Cancer Infusion Could Soon Be Cut to 5 Minutes—and Celltrion Wants to Lead It

Celltrion has applied for EMA approval of Herzuma SC, a new breast cancer treatment, enhancing drug delivery and patient convenience.

Celltrion Launches New Autoimmune Drug Avtozma in Japan

Celltrion launches Avtozma for autoimmune diseases in Japan, expanding its product portfolio and strengthening market presence.

Unlocking Cancer Treatment: Celltrion’s 4 Promising ADC Drugs Enter Patient Trials in 2026

Celltrion's ADC cancer drug candidates CT-P70, CT-P71, and CT-P73 enter patient dosing, targeting various cancers with Fast Track Designation.

Celltrion’s Steqeyma IV Approval: What This Means for Celltrion’s Growth in Japan’s Autoimmune Drug Market

Celltrion's Steqeyma IV formulation gains approval in Japan, expanding treatment for Crohn's disease and enhancing market competitiveness.

Celltrion sees prescription growth for key products in Europe, raises expectations for high-margin new drugs

Celltrion's cancer and autoimmune disease treatments are achieving stable growth in Europe, expanding their market influence.

How is Omlyclo Revolutionizing Allergy Treatment in Europe: Key Successes and Insights

Celltrion's Omlyclo treatment is rapidly gaining market share in Europe, winning tenders and expanding prescriptions across multiple countries.

Truxima: How the First Korean Biosimilar Achieved 35.8% Market Share in the U.S.!

Celltrion’s Truxima becomes South Korea's first biosimilar to lead U.S. prescription market, boosted by tariff exemptions and strong growth.

CT-P71: The New ADC Cancer Drug Fast-Tracked by FDA for Urothelial Carcinoma

Celltrion's CT-P71 receives FDA Fast Track designation for urothelial carcinoma, enhancing its ADC pipeline and global drug development efforts.

How Celltrion’s Local Production Strategy Eliminates U.S. Drug Tariffs Influence

Celltrion resolves tariff impacts on U.S. sales, boosting local production and growth opportunities for its biosimilars, including Zymfentra.

Celltrion Launches Omlyclo in Brazil: How This First Mover is Revolutionizing Autoimmune Treatment

Celltrion launched Omlyclo in Brazil, aiming to boost market penetration and strengthen ties with local medical professionals.

Celltrion’s Groundbreaking Achievement: First Asian Bio Company to Secure APEC CBPR and Global CBPR Certifications

Celltrion becomes the first South Korean biotech firm to earn APEC CBPR and Global CBPR certifications, enhancing global data protection.

Celltrion’s 1 Trillion KRW Investment: A Game Changer for Biopharmaceutical Production by 2030

Celltrion plans a major expansion with over 1 trillion KRW investment, boosting production capacity for biosimilars and new drugs by 2030.

Why Celltrion’s STEQEYMA Auto-Injector is a Game Changer for Autoimmune Patients in North America

Celltrion expands its Steqeyma auto-injector lineup in Canada, enhancing market competitiveness and patient accessibility in North America.

How Zymfentra’s Prescription Rates Tripled in January: A Game-Changer for Celltrion

Celltrion's Zymfentra sees a 213% rise in U.S. prescriptions, marking significant growth since its launch, driven by market demand.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.